Merz Pharma acquires Swiss aesthetic medicine specialist Anteis

14 Nov 2013

Merz Pharma has further strengthened its position in the aesthetics market by purchasing the Swiss company Anteis S.A.  Anteis specialises in the development, manufacture and commercialisation of biomedical products in the area of aesthetics.   

Merz Pharma has further strengthened its position in the aesthetics market by purchasing the Swiss company Anteis S.A.  Anteis specialises in the development, manufacture and commercialisation of biomedical products in the area of aesthetics. 

The acquisition strengthens Merz Aesthetics’ portfolio and reinforces its market position in the field of aesthetic medicine while merging Anteis’ operations into one of the leading providers worldwide.

“The acquisition of Anteis by Merz is a unique opportunity to strengthen our presence in aesthetic medicine by bringing innovative solutions to doctors and patients,” says Philip Burchard, CEO Merz Pharma. “Anteis brings substantial additions to Merz in terms of products, talent, geographic presence and manufacturing capabilities, our two portfolios’ complement each other perfectly.”

 Since 2005, Merz Pharmaceuticals has distributed Belotero® range of fillers, developed by Anteis.  In less than 10 years, Anteis has become a strong global player in the area of injectable medical devices based on biopolymer transformation. 

Anteis has developed several highly innovative and highly differentiated products in the field of aesthetics, e.g. wrinkle-filling gels, resorbable implants and cutaneous rehydration gels. Their product lines Esthélis, Fortélis, Mesolis and Modélis as well as the Jolidermis range and the Anteis Injection System are available in over 90 countries in five continents. Besides aesthetic dermatology, Anteis is also active in the fields of ophthalmology and orthopedics. 

Comments

Log-in to post a comment